AU772911B2 - Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders - Google Patents

Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders Download PDF

Info

Publication number
AU772911B2
AU772911B2 AU44322/99A AU4432299A AU772911B2 AU 772911 B2 AU772911 B2 AU 772911B2 AU 44322/99 A AU44322/99 A AU 44322/99A AU 4432299 A AU4432299 A AU 4432299A AU 772911 B2 AU772911 B2 AU 772911B2
Authority
AU
Australia
Prior art keywords
secretin
individual
effective amount
disorder
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU44322/99A
Other languages
English (en)
Other versions
AU4432299A (en
Inventor
Victoria Beck
Bernard Rimland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repligen Corp
Original Assignee
Repligen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repligen Corp filed Critical Repligen Corp
Publication of AU4432299A publication Critical patent/AU4432299A/en
Application granted granted Critical
Publication of AU772911B2 publication Critical patent/AU772911B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU44322/99A 1998-06-09 1999-06-09 Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders Ceased AU772911B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8857598P 1998-06-09 1998-06-09
US60/088575 1998-06-09
US09/229,208 US6197746B1 (en) 1998-05-19 1999-01-13 Method of using secretin for treating autism
US09/229208 1999-01-13
PCT/US1999/013061 WO1999064059A2 (en) 1998-06-09 1999-06-09 Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders

Publications (2)

Publication Number Publication Date
AU4432299A AU4432299A (en) 1999-12-30
AU772911B2 true AU772911B2 (en) 2004-05-13

Family

ID=26778819

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44322/99A Ceased AU772911B2 (en) 1998-06-09 1999-06-09 Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders

Country Status (8)

Country Link
US (3) US6197746B1 (https=)
EP (1) EP1085901B1 (https=)
JP (1) JP2002517467A (https=)
AT (1) ATE322283T1 (https=)
AU (1) AU772911B2 (https=)
CA (1) CA2333657A1 (https=)
DE (1) DE69930739D1 (https=)
WO (1) WO1999064059A2 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2290556A1 (en) * 1997-05-19 1998-11-26 Repligen Corporation Method for assisting in differential diagnosis and treatment of autistic syndromes
US6197746B1 (en) * 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
US6020314A (en) * 1998-08-11 2000-02-01 Milkhaus Laboratory, Inc. Methods for treatment of neurological disorders
WO2001037801A1 (en) * 1999-11-22 2001-05-31 Rogoff Joseph A Secretin and secretin pharmaceuticals for treating attention deficit disorder
US6632429B1 (en) * 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US6534063B1 (en) 1999-12-17 2003-03-18 Joan M. Fallon Methods for treating pervasive development disorders
GB0008326D0 (en) * 2000-04-06 2000-05-24 Shs International Ltd Diagnosis and treatment of autism and related disorders
GB0016441D0 (en) 2000-07-04 2000-08-23 Pharmagene Lab Limited Therapeutic method
WO2002014537A2 (en) * 2000-08-14 2002-02-21 Fallon Joan M Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
DE60131032T2 (de) * 2000-08-25 2008-08-14 Research Corp. Technologies, Inc., Tucson Verwendung von antikonvulsiven Aminosäure zur Behandlung von Migräne
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
GB0118383D0 (en) * 2001-07-27 2001-09-19 Pharmagene Lab Ltd Therapeutic methods
US6585996B1 (en) 2002-03-13 2003-07-01 Westlake Laboratories, Inc. Lipid-soluble thiamine derivatives in the treatment of autism
US8100844B2 (en) * 2002-04-25 2012-01-24 Ultraflex Systems, Inc. Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
US20070154534A1 (en) * 2003-03-12 2007-07-05 Sheitman Brian B Use of secretin in the treatment of schizophrenia
EP1605960A2 (en) * 2003-03-12 2005-12-21 Repligen Corporation Use of secretin and secretin analogs to treat affective disorders
WO2004100899A2 (en) * 2003-05-13 2004-11-25 The Mclean Hospital Corporation Use of secretin in treatments of disorders associated with the amygdala
US7947285B2 (en) * 2003-12-12 2011-05-24 Fein Seymour H Methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis
US7381698B2 (en) * 2003-12-12 2008-06-03 Chirhoclin, Inc. Methods for treatment of acute pancreatitis
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
GB0504096D0 (en) * 2005-02-28 2005-04-06 Tipogen As Method
US20070034214A1 (en) * 2005-08-12 2007-02-15 Dochniak Michael J Method to affect the development of autism spectrum disorders
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US8658163B2 (en) * 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
PL2318035T3 (pl) * 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
KR20170005191A (ko) 2009-01-06 2017-01-11 큐어론 엘엘씨 이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법
CN102300989B (zh) 2009-01-06 2015-12-09 柯尔朗恩有限责任公司 用于治疗或预防金黄色葡萄球菌感染以及用于根除或减少表面上金黄色葡萄球菌的组合物和方法
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
EP2485744A4 (en) * 2009-10-09 2014-01-22 Prothera Inc COMPOSITIONS AND METHODS COMPRISING THE PEDIOCOCCUS TO REDUCE AT LEAST ONE SYMPTOM ASSOCIATED WITH DEVELOPMENT-INVASIVE DISORDER IN A PERSON IN WHICH A DEVELOPMENT-INVASIVE DISORDER HAS BEEN DIAGNOSED
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
JP5902148B2 (ja) * 2010-03-31 2016-04-13 アベラ ファーマスーティカルズ インコーポレイテッド 自閉症治療用ジメチルスルホキシド（ｄｍｓｏ）製剤
US9931365B2 (en) 2010-09-28 2018-04-03 Lisa Geng Methods for treating neurological disorders using nutrient compositions
WO2012050895A1 (en) 2010-09-28 2012-04-19 Lisa Geng Methods for treating neurological disorders using nutrient compositions
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
WO2012177647A2 (en) 2011-06-20 2012-12-27 Kerry Lane Mycotoxin diagnostics and methods thereof
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
AU2018250823A1 (en) 2017-04-10 2019-10-17 Curemark, Llc Compositions for treating addiction
US11318190B2 (en) * 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
CN109908120B (zh) * 2019-04-22 2022-04-19 井冈山大学 一种狭顶鳞毛蕨有效成分、提取方法及其应用
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833722A (en) * 1971-03-16 1974-09-03 D Graybill Method for controlling allergies
WO1998052593A1 (en) * 1997-05-19 1998-11-26 Repligen Corporation Method for assisting in differential diagnosis and treatment of autistic syndromes

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5029005B2 (https=) * 1972-05-08 1975-09-19
US3987014A (en) 1974-01-10 1976-10-19 Becton, Dickinson And Company Secretin intermediates and derivatives
DE2615229C2 (de) 1976-04-08 1984-05-24 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung und Reinigung von Sekretin
US4086220A (en) 1976-08-09 1978-04-25 G. D. Searle & Co. Fragments of secretin
ES492206A0 (es) 1979-06-13 1980-12-16 Hoechst Ag Procedimiento para la preparacion de un preparado de secre- tina con efecto reforzado y retardado
NZ196349A (en) 1980-03-07 1984-08-24 Interx Research Corp Enhancement of absorption rate of orally administered polar bioactive agents
JPS58140024A (ja) 1982-02-15 1983-08-19 Eisai Co Ltd セクレチンの精製方法
DE3328793A1 (de) 1983-08-10 1985-02-28 Hoechst Ag, 6230 Frankfurt Herstellung von sekretin
SE454513B (sv) 1985-03-11 1988-05-09 Kabigen Ab Humant sekretin samt kompositioner innehallande detta
JPS61277618A (ja) 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
US5008251A (en) 1986-03-27 1991-04-16 The Regents Of The University Of California Method of treating autism
US4994467A (en) 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
US5094837A (en) 1990-01-22 1992-03-10 Wayne State University Method for use of magnetic resonance imaging to image pancreas using secretin
US5225407A (en) 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
US5380872A (en) * 1992-07-14 1995-01-10 Glaxo Inc. Modulators of cholecystokinin
DE69426415T2 (de) 1993-01-29 2001-07-26 Aradigm Corp., Hayward Intrapulmonares hormonabgabesystem
US5527825A (en) 1994-04-06 1996-06-18 University Of Arkansas Method of treating schizophrenia, tourette's syndrome, mania, autism, and obsessive compulsive disorder with inhibitors of brain nitric oxide synthase
US5560910A (en) * 1994-08-26 1996-10-01 Crandall; Wilson T. Topical anti-inflammatory composition and method
GB9417524D0 (en) 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
US5686311A (en) 1995-06-23 1997-11-11 The Children's Mercy Hospital Diagnosis of autism and treatment therefor
US6197746B1 (en) * 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
WO1999013061A1 (en) 1997-09-11 1999-03-18 The Regents Of The University Of California Plus end-directed microtubule motor required for chromosome congression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833722A (en) * 1971-03-16 1974-09-03 D Graybill Method for controlling allergies
WO1998052593A1 (en) * 1997-05-19 1998-11-26 Repligen Corporation Method for assisting in differential diagnosis and treatment of autistic syndromes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HORVATH (1998) J. ASSOC ACA. MIN. PHYS. V9(1) P 9-15 *

Also Published As

Publication number Publication date
EP1085901A2 (en) 2001-03-28
DE69930739D1 (de) 2006-05-18
AU4432299A (en) 1999-12-30
US20010049353A1 (en) 2001-12-06
WO1999064059A3 (en) 2000-03-02
US6197746B1 (en) 2001-03-06
US20050249714A1 (en) 2005-11-10
WO1999064059A2 (en) 1999-12-16
EP1085901B1 (en) 2006-04-05
ATE322283T1 (de) 2006-04-15
JP2002517467A (ja) 2002-06-18
US6790825B2 (en) 2004-09-14
CA2333657A1 (en) 1999-12-16

Similar Documents

Publication Publication Date Title
AU772911B2 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
Castaigne et al. Paramedian thalamic and midbrain infarcts: clinical and neuropathological study
US4432975A (en) Process for introducing vitamin B-12 into the bloodstream
Aird et al. Anticonvulsive properties of desoxycorticosterone
JP2014506254A (ja) β−ヒドロキシ−β−メチルブチレートを用いる廃用期間後の筋肉回復を促進させるための方法
MIER et al. Acanthrocytosis, pigmentary degeneration of the retina and ataxic neuropathy: a genetically determined syndrome with associated metabolic disorder
JP2002501616A (ja) 自閉的症候群を鑑別診断および治療する際の助けとするための方法
Dropcho et al. Paraneoplastic opsoclonus-myoclonus: association with medullary thyroid carcinoma and review of the literature
CN1711101A (zh) 孤独症及相似障碍的治疗
RU2195297C2 (ru) Способ лечения дистрофических заболеваний глаз
US11564958B2 (en) Compositions and methods of treatment of Ehlers-Danlos syndromes
Ceccarelli et al. Clinical and electrophysiological reports in a case of early onset myotonia congenita (Thomsen's disease) successfully treated with mexiletine
CN114306207A (zh) 一种以棒棒糖为载体的口腔给药方法
CN119212574A (zh) 用于降低血糖的水解胶原蛋白
Loeb The venom of Heloderma
Restivo et al. Trismus after stroke/TBI: botulinum toxin benefit and use pre-PEG placement
RU2153891C2 (ru) Способ лечения эпилепсии у детей
Helms et al. 12 Movement Disorders That Imitate Epilepsy
Frucht et al. Unusual Movement Disorders
RU2329761C2 (ru) Способ лечения абсансов при идиопатической генерализованной эпилепсии у детей
EP0012774A1 (en) Vegetative stigmata therapeutic agent
RU2219936C2 (ru) Способ лечения хронического слухового галлюциноза, резистентного к терапии
RU2548712C2 (ru) Способ лечения эпилепсий
WO2001037801A1 (en) Secretin and secretin pharmaceuticals for treating attention deficit disorder
Shulman That Imitate Epilepsy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)